Literature DB >> 12106954

Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.

Roger L White1, Kevin A Enzweiler, Lawrence V Friedrich, David Wagner, Daryl Hoban, John A Bosso.   

Abstract

The susceptibility of 4009 recent clinical isolates of Streptococcus pneumoniae to gatifloxacin, levofloxacin, ciprofloxacin, penicillin, ceftriaxone and azithromycin was determined. Overall rates of susceptibility to these agents were 99.4, 98.7, 71.2, 55.2, 80.9, and 71.3%, respectively. Resistance to all tested agents was associated with penicillin resistance. Of penicillin nonsusceptible isolates, 36% were resistant. Resistance to the fluoroquinolones was unusual and gatifloxacin generally appeared to be four-fold more active than levofloxacin or ciprofloxacin. Multidrug resistant S. pneumoniae accounted for 6.2% of this sample. The lowest rate of susceptibility to non-fluoroquinolone antibiotics was observed in isolates from the South region of the United States, which appeared to be explained by both the proportion of and the inherently higher MICs of certain types of isolates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106954     DOI: 10.1016/s0732-8893(02)00391-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Pharmacokinetics of gatifloxacin in infants and children.

Authors:  Edmund V Capparelli; Michael D Reed; John S Bradley; Gregory L Kearns; Richard F Jacobs; Bharat D Damle; Jeffrey L Blumer; Dennis M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Antimicrobial susceptibility of invasive and lower respiratory tract isolates of Streptococcus pneumoniae, 1998 to 2007.

Authors:  Otto G Vanderkooi; Athena McConnell; Deirdre L Church; James D Kellner
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 3.  Drug treatment of pneumococcal pneumonia in the elderly.

Authors:  Sridhar Neralla; Keith C Meyer
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Authors:  Lionel A Mandell; John G Bartlett; Scott F Dowell; Thomas M File; Daniel M Musher; Cynthia Whitney
Journal:  Clin Infect Dis       Date:  2003-11-03       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.